. Effect COX-2, cyclooxygenase-2; DMT1-IRE, divalent metal transporter 1 with iron responsive element; ERK, extracellular-signal-regulated kinases; GSH, glutathione; FP1, ferroportin1; iNOS, inducible nitric oxide synthases; IRPs, iron regulatory proteins; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MMP, mitochondria membrane potential; MPP, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PGE2, prostaglandin E2; ROS, reactive oxygen species; SN, substantia nigra; TH, tyrosine hydroxylase; T-SOD, total superoxide dismutase; 6-OHDA, 6-hydroxydopamine.
of locomotor dysfunction in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/MPP(+)-induced C57BL/6 mice and Sprague-Dawley (SD) rats. Thus, P. ginseng extracts appear to provide protective effects against neurotoxicity in vitro and in vivo models of PD.
Rg1
Rg1, one of the biologically active ingredients of P. ginseng, may be a candidate neuroprotective drug. Rg1 increases the contents of dopamine and its metabolites in the striatum as well as increasing TH expression in the SN of MPTP-treated C57BL/6 mice by attenuating elevated iron levels, decreasing divalent metal transport 1 (DMT1) expression, and increasing ferroportin1 expression in the SN [18] . Consistent with these in vivo observations, Rg1 attenuates DMT1 up-regulation and cellular iron uptake in the MPP+ or 6-hydroxydopaminetreated MES23.5 cells [19, 20] . Elevated iron levels in the SN participate in neuronal death in neurodegenerative diseases including PD by enhancing the generation of free radicals and oxidative stress [21, 22] . Suppressing oxidative stress mediates the neuroprotective effects of Rg1 in MPTP-induced SN [23, 24] . Within 24 h following MPTP treatment, pretreatment of with Rg1 prevents the activation of glutathione reduction and total superoxide dismutase (SOD), and attenuates the phosphorylation of c-Jun, N-terminal kinase and c-Jun in SN of C57BL/6 mice [23] . Also, pretreatment with Rg1 markedly reduces the generation of dopamine-induced ROS and the release of mitochondrial cytochrome C into the cytosol and inhibits the activation of caspase-3, inducible nitric oxide synthase (iNOS) protein level and nitric oxide (NO) production in dopamine-induced PC12 cells [25] . Rg1 also can protect SN neurons by regulating the insulinlike growth factor-I receptor signaling pathway [24] , the phospho (p)-extracellular signal regulated kinases (ERK)1/2, and p-p38 mitogen-activated protein kinases (MAPKs) signaling pathways [26, 27] .
Recently, Leung et al. [28] reported that Rg1 has neuroprotective effects for primary SN neurons against rotenone toxicity, because Rg1 prevents cytochrome C release from the mitochrondrial membrane and increases the phosphorylation inhibition of the pro-apoptotic protein Bad through the activation of the phosphoinositide-3-kinase (PI3K)/Akt pathway. More recently, Liu et al. [29] proved that pretreatment with Rg1 can markedly reduce the cytotoxicity induced by hydrogen peroxide (H 2 O 2 ) in PC12 cells by inhibiting nuclear factor-kappa B (NF-κB) activation. In their study, the NF-κB signaling pathway was thoroughly activated by H 2 O 2 in PC12 cells and pretreatment with Rg1 suppressed phosphorylation and nuclear translocation of NF-κB/p65, and phosphorylation and degradation of inhibitor protein of κB (IκB) as well as the phosphorylation of IκB-kinase complex. Rg1 also inhibited the activation of Akt and the ERK1/2. Furthermore, the protection of Rg1 on H 2 O 2 -injured PC12 cells was attenuated by pretreatment with two NF-κB pathway inhibitors (JSH-23 or BOT-64) [29] .
Re and Rd
Re and Rd have neuroprotective effect in neurotoxicity of SN. Pretreatment with Re has been reported to markedly increase TH(+) neurons and to decrease the terminal deoxynucleotidyl transferase dUTP nick end labeling(+) ratio compared with MPTP-treated wild type mice. Furthermore, Re enhances the expression of bcl-2 protein and bcl-2 mRNA, but reduces the expressions of bax, bax mRNA, and iNOS, and weakens the cleavage of caspase-3 [30] . In addition, Rd inhibits loss of dendritic processes, changes in the perikarya, cellular atrophy and neuronal cell loss of TH(+) cells in mesencephalic primary cultures treated with lipopolysaccharide (LPS) by reducing NO-formation and PGE2 synthesis [31] . Thus, P. ginseng and its various elements may provide a potential means of slowing the progress of PD.
Alzheimer's disease
Alzheimer's disease (AD), the most common cause of dementia in elderly people, is a neurodegenerative disease characterized by senile plaque deposition, neurofi brillary tangle formation, and neuronal loss. The key mechanism leading to AD pathogenesis is the abnormal metabolism of amyloid precursor protein (APP) [32, 33] . The AD b rain is characterized by a variety of alterations in cellular and molecular mechanisms, including amyloid beta (Aβ) clearance capability, mitochondrial function, synaptic dysfunction, down-regulation of anti-oxidant, up-regulation of oxidative stress, and inflammatory response [34] [35] [36] . Mo st ther apeutic strategies for AD only provide symptomatic treatment, including inhibition of generation or aggregation of Aβ, enhancement of the removal of Aβ from the neurons, interruption of tau hyperphosphorylation, and the use of more effi cacious antioxidant and anti-infl ammatory drugs [37] [38] [39] . However, no drug has yet been found to prevent the progressive loss of neurons in AD patients [32] [33] [34] [35] [36] [37] [38] [39] .
Extracts
Recent evidence has shown the effectiveness of P. ginseng extract and powder and various ginsenosides AD, Alzheimer's disease; Aβ, amyloid beta; AchE, acetylcholinesterase; ADAS, Alzheimer's disease assessment scale; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; CaMKII, Ca 2+ /calmodulin-dependent protein kinases II; ChAT, choline acetyltransferase; CDK5, cell division protein kinase 5; CDR, clinical dementia rating; COX-2, cyclooxygenase-2; CREB, cAMP response element-binding; DEX, dexamethasone; ERK, extracellular-signal-regulated kinases; GSK-3, glycogen synthase kinase-3; IFN-γ, interferon-gamma; IkB, inhibitor of kB; IKK, IkB kinase; IL, interleukin; K-MMSE, Korean version of the mini-mental status examination; LDH, lactate dehydrogenase; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; MDA, malondialdehyde; MMSE, mini-mental state examination; NEP, neprilysin; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; NMDAR1, N-methyl-D-aspartate receptor 1; nNOS, neuronal nitric oxide synthases; NO, nitric oxide; NR, N-methyl D-aspartate receptor; PACAP, pituitary adenylate cyclase-activating polypeptide; PKA RIIα, isoform II alpha of the regulatory subunit protein kinase A; PKC, protein kinase C; PP2A, protein phosphatase 2A; PSD-95, postsynaptic density protein 95; ROS, reactive oxygen species; SAMP8, senescence-accelerated mouse prone 8; SweAPP, Swedish mutant β-amyloid precursor protein; TNF-α, tumor necrosis factors-α.
on AD using in vitro and in vivo models (Table 2) [40] [41] [42] [43] . Patients receiving Korean red ginseng powder (9.0 g/d) or Korean white ginseng powder (4.5 g/d) showed significant improvement on the AD assessment scale, the mini-mental state examination scores, and the clinical dementia rating after 12 wk of ginseng therapy when compared with those in the control group [40, 41] . Longterm (for 7 mo) consumption of ginseng total saponins (100 and 200 mg/kg/d) demonstrated signifi cant prevention of the memory loss in aged senescence-accelerated mouse prone 8 (SAMP8) mice by decreasing oxidative stress and up-regulating plasticity-related proteins that include postsynaptic density protein 95, p-N-methyl-Daspartic acid receptor 1 (p-NMDAR1), p-Ca 2+ /calmodulin-dependent protein kinases II, p-protein kinase A (p-PKA) catalytic β subunit, p-protein kinase Cγ subunit, pcyclic adenosine monophosphate (p-cAMP), p-cAMP response element-binding (p-CREB), and brain derived neurotrophic factor (BDNF) in the hippocampus [42] . It also has been suggested that P. ginseng extracts bestow neuroprotection by regulating the phosphatase activity of purifi ed calcineurin and tau phosphorylation in SY5Y human neuroblastoma cells [43] . Calcineurin, a Ca 2+ / calmodulin-dependent protein phosphatase, plays an important role in tau hyperphosphorylation, which is one of the neuropathologic features in the brains of AD patients [43] .
Rb1
In vitro, Rg1 protects neurons against the neuronal toxicity (shrunken perikaryon with loss of neurite processes) of Aβ1-42, most likely through an anti-oxidant pathway; Lactate dehydrogenase release, malondialdehyde (MDA) production, and SOD activity in Aβ1-42-treated neurons were all markedly decreased [44] . Pretreatment with Rb1 for 24 h inhibits Aβ25-35-induced ROS overproduction and lipid peroxidation in PC12 cells, and increases bcl-2/bax and caspase-3 activation, thereby improving cell survival [45] . Pretreatment with Rb1 significantly attenuates Aβ1-42 or 25-35-induced neurotoxicity and tau hyperphosphorylation both in vivo and in vitro [46, 47] . Rb1 also increases the levels of p-Ser (473)-Akt and down-regulates glycogen synthase kinase-3β activity by activation of PI3K [46] . Consistent with these reports, Rb1 attenuates the mRNA levels of calpain and p25 of cell division protein kinase 5 pathway in primary cultured cortical neurons [47] , and Rb1 reverses the changes in several direct or indirect neuroinfl ammation markers (COX-2, IkB-α, and neuronal NOS) at multiple ADrelated sites in primary cortical neurons [48] .
Rg1
Rg1 inhibits the activation of NF-κB/p65, Akt and the ERK1/2 in H 2 O 2 -induced PC12 cells [29] . Rg1 also inhibits the expression of caspase-3 to obviate apoptosis in brain slices from AD model rats [49] and in Chinese hamster ovarian tumor cells transfected with mutant PSIM146L gene and WT APP751 gene (mutant PSM146L/APP751 cells) stably producing excessive Aβ1-42 [50] . Consistent with these reports, Wang et al. [51] reported that treatment with Rg1 (5 and 10 mg/ kg, for 10 d) ameliorates the Aβ25-35-induced learning and memory impairment by preventing the cortical and hippocampal choline acetyltransferase activity decline induced by Aβ25-35, and by inhibiting the activity of acetylcholinesterase [51] . And Li et al. [52] reported that treatment with Rg1 (6.5 mg/kg, for 21 d) improves learning and memory by downregulating the mRNA level of caspase-3, decreasing the expressions of caspase-3 and cytochrome C in the hippocampus and neocortex, and inhibiting the activity of caspase-9 and caspase-3 in 12-month-old male mice chronically treated with stressful levels of dexamethasone.
Long-term consumption (for 3 months) of Rg1 could attenuate hippocampal Aβ contents and improve learning and memory outcomes in SAMP8 mice by decreasing PKA RIIα level (isoform IIα of the regulatory subunit of PKA) and increasing p-CREB and BDNF levels in the hippocampus [53] . Rg1 reduces Aβ42 levels in cell-based assays and in the brains of Tg2576 mice, a mouse model of Aβ accumulation [54] . Rg1 protects Aβ25-35-induced cytotoxicity in PC12 cells by inhibiting β-secretase activity [55] . Also, high-dose Rg1 (240 µM) decreases the expression of p-tau and increases the expressions of NMDAR1 and NMDAR2B in okadaic acid-treated brain slices in a 5-week-old Wister rat model of AD [56, 57] .
Gong and Zhang [58] showed that Rg1 could prevent the toxicity of Aβ25-35 and/or interferon (IFN)-γ to microglia, inhibit microglial respiratory burst activity and decrease the accumulation of NO. The results are consistent with a neuroprotective effect of Rg1 against damage by reactive microglia in AD. Interestingly, Joo et al. [59] discovered that Rb1 and Rg1 exert opposite effects in a dose-dependent manner (50-250 µg/mL). In their report, whereas Rg1 stimulated NO and the proinflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α in LPS-treated primary microglial cultures from rats, Rb1 exerted a signifi cant inhibitory effect on this proinfl ammatory repertoire [59] . Moreover, when a combined treatment with equal doses of Rb1 and Rg1 was given, Rb1 significantly counteracted the stimula-http://ginsengres.org tory effects of Rg1 for 72 h, as evidenced by NO assay results [59] . These results suggest that neurodegenerative diseases such as AD, which are caused primarily by cell death due to chronic infl ammation and cell stress, might be controlled by proper doses of non-toxic, natural Rg1 and Rb1 [59] .
Rg2
Rg2 is a protopanaxatriol-type compound that is one of the major active components in the root and stem leaves of P. ginseng. It has been suggested that Rg2 acts by a wide range of mechanisms [60, 61] . Rg2 attenuates glutamate-induced neurotoxicity in PC12 cells as judged by decreased the cell viability, increased intracellular Ca 2+ concentration, lipid peroxidation (i.e., excessive production of MDA and NO), and the protein expression levels of calpain II, caspase-3, and Aβ1-40 [60] . It also has been reported that Rg2 protects from memory impairment via anti-apoptosis in a rat model of vascular dementia [61] .
Rg3
Microglia are phagocytic cells that are the major infl ammatory response cells of the central nervous system (CNS). They have important pathophysiologic roles in AD in both potentially neurotoxic responses and potentially benefi cial phagocytic responses [62] . Joo and Lee [63] examined whether Rg3 enhances the microglial phagocytosis of Aβ. They found that Rg3 promotes Aβ uptake, internalization, and digestion. Increased maximal Aβ uptake was observed at 4 and 8 h after pretreatment with Rg3, and the internalized Aβ was almost completely digested from cells within 36 h. In the report, the expression of type A macrophage scavenger receptor (MSRA) was also up-regulated by Rg3 treatment in dose-and time-dependent manners in the cytosol. The authors suggested that microglial phagocytosis of Aβ may be enhanced by Rg3, that the effect of Rg3 on promoting clearance of Aβ may be related to the MSRA-associated action of Rg3, and that stimulation of the MSRA might contribute to the therapeutic potentials of Rg3 in microglial phagocytosis and digestion in the treatment of AD [63] . Moreover, it was has been reported that Rg3 signifi cantly reduces the levels of Aβ40 and Aβ42 in SK-N-SH cells transfected with Swedish mutant β-amyloid precursor protein by enhancing neprilysin gene expression, the ratelimiting enzyme in the Aβ degradation in the brain [64] .
Re and Rh2
It has been reported that reactive astrocytes induced by Aβ contributes to disease progression in AD [62] . Shieh et al. [65] found that Rh2 stimulates the gene expression of the neurotrophic factor, pituitary adenylate cyclaseactivating polypeptide to promote cell survival and cell proliferation in type I rat brain astrocytes. The results suggest that Rh2 attenuates Aβ-induced toxicity. Chen et al. [54] reported that Re reduces signifi cantly Aβ42 levels in cell-based assays and oral administration reduces signifi cantly Aβ levels in the brains of Tg2576 mice. Thus, P. ginseng itself and its various constituents may provide a potential means of slowing the progress of AD.
Gintonin
Recently, gintonin, newly identifi ed compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affi nity [66] . Hwang et al. [67] investigated the effect of gintonin using in vitro and in vivo models in AD. In the study, gintonin promoted sAβPPα release in concentration-and time-dependent manners and decreased Aβ1-42 release and attenuated Aβ1-40-induced cytotoxicity in SH-SY5Y cells. Gintonin also rescued Aβ1-40-induced cognitive dysfunction in mice. Moreover, in a transgenic mouse AD model, long-term oral administration of gintonin attenuated amyloid plaque deposition as well as short-and longterm memory impairment [67] . These results suggest that gintonin could be a useful agent for AD prevention or therapy.
Huntington's disease
Huntington's disease (HD) is a hereditary neurological disorder of the CNS that causes progressive degeneration of striatal cells in the brain. HD is characterized clinically by involuntary abnormal movements, psychiatric disturbance, and cognitive defi cit and pathologically by degeneration of the gamma-aminobutyric acid-ergic medium size spiny neurons [68] . HD originates due to the mutation of the gene encoding the huntingtin (htt)-protein.
The underlying genetic mutation has been identified as a CAG-repeat expansion in the IT15 gene of chromosome 4 [69] . The formation of mutant htt protein leads to mitochondrial dysfunction, caspase activation, apoptosis, excitotoxicity, and RNA dysregulation. Recent evidence suggests that microglial activation is also an integral part of HD pathogenesis [70, 71] . However, the exact mechanisms linking the formation of the mutant htt protein to neuronal cell death in the striatum are unclear [72] . There are no current drug therapies proven to help ameliorate or abrogate the disease process in HD.
Ginseng total saponins
Ginseng total saponins (GTS) and its compounds, which are the major active ingredients of P. ginseng, have protective effects against neurotoxin insults (Table 3 ) [73, 74] . To test the neuroprotective activity of GTS and its compounds, Kim et al. [73] examined the in vitro and in vivo effects of GTS on striatal neurotoxicity induced by repeated treatment of the succinic dehydrogenase inhibitor 3-nitropropionic acid (3-NP) in rats. Because administration of 3-NP induces a selective striatal pathology similar to that seen in HD, it has been widely used as an animal model of HD [75, 76] . Kim et al. [73] reported that systemic administration of GTS can significantly improve 3-NP-induced behavioral impairment and extend the survival of SD rats. To explain the mechanisms underlying the in vivo protective effects of GTS against 3-NP-induced striatal degeneration, the authors examined the in vitro effect of GTS against 3-NP-mediated cytotoxicity using cultured rat striatal neurons. GTS inhibited 3-NP-induced elevation of intracellular Ca 2+ concentration and restored the 3-NP-induced mitochondrial transmembrane potential reduction in cultured rat striatal neurons. As well, the authors reported that GTS prevented 3-NP-induced striatal neuronal cell deaths in a dose-dependent manner [73] . The results suggest that the in vivo protective effects of GTS against 3-NP-induced rat striatal degeneration might be achieved by inhibition of 3-NP-induced intracellular Ca 2+ elevations and cytotoxicity of striatal neurons.
Recently, activated microglia have been proposed to play a major role in the pathogenesis of a range of neurodegenerative diseases including HD [71, 77] . And GTS and Rh1 have been reported to have an anti-infl ammatory mechanism in LPS-stimulated microglia [78, 79] . Based on these results, we studied whether P. ginseng extract has a neuroprotective effect in 3-NP-stimulated striatal toxicity of mice. We confi rmed that pretreatment (for 10 d) and co-treatment (before 1 h) with P. ginseng extract improved clinical behavior and striatal neuronal death by regulating microglial activation, infl ammatory mediators (iNOS, TNF-α, IL-6, and IL-1β), and activation of p38 and ERK1/2 MAPKs signaling pathways (unpublished).
Ginsenosides
To assess the neuroprotective activity of compounds of GTS, Wu et al. [74] tested 10 different ginsenosides in a previously developed in vitro HD assay with primary medium spiny striatal neuronal cultures (MSN) from a YAC128 HD mouse model. Pretreatment with Rb1 (0.01-0.1 µM), Rc (0.01 µM), and RG5 (1.0 µM) effectively protected YAC128 medium spiny neurons from apoptosis induced by 250 µM glutamate. However, the other seven ginsenoside samples (Rd, Re, Rg3, Rh1, mixture of Re and Rd, mixture of Rk1 and Rg5, and mixture of Rh4 and Rk3) had no protective effects on glutamate-induced apoptosis of YAC128 MSN at the concentrations tested and Re, Rh1, and mixture of Rk1 and Rg5 were actually toxic to MSN at 1 μM [74] . From further experiments, the authors suggested that the neuroprotection bestowed by Rb1, Rc, and Rg5 could correlate with their ability to inhibit glutamate-induced Ca 2+ responses in cultured MSN [74] . From these results, the authors concluded that Rb1, Rc, and Rg5 offer a potential therapeutic choice for the treatment of HD and possibly other neurodegenerative disorders [74] .
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig's disease and motor neuron disease, is a disease of the motor nervous system caused by the degeneration of upper and lower neurons, located in the ventral horn of the spinal cord and cortical neurons that provide their efferent input. ALS is characterized by rapidly progressive weakness, muscle atrophy and fasciculations, spasticity, dysarthria, dysphagia, and respiratory compromise. Sensory function generally is spared, as are autonomic and oculomotor activity [80] [81] [82] [83] . ALS is a progressive and neurodegenerative disease with most affected patients dying of respiratory compromise and pneumonia within 2 to 3 yr after the onset of symptoms [84] . Familial cases of ALS are known, but most cases of ALS (>90%) are sporadic and are likely caused by multi-factorial factors [85, 86] , although the causes and underlying mechanisms are not completely understood. Many ALS patients use unconventional or alternative therapies, of uncertain effi cacy or toxicity. One example is ginseng root, long used in natural or traditional therapies for a variety of ailments. The herbal remedies, P. quinquefolium, P. japonicus, and Rb2 have recently been demonstrated to possess neuroprotective and neurotrophic properties [87] [88] [89] [90] , which may be useful in vivo and in vitro models of ALS.
Panax quinquefolium/japonicus and ginsenosides
In a study using mutant SOD1 transgenic mice [B6SJL-TgN(SOD-1G93A)1Gur], the relevant animal model for ALS, it was reported that crude ginseng powder from P. quinquefolium signifi cantly delay the onset of signs (116 d vs. 94 d) of motor impairment and prolong the survival (139 d vs. 132 d) of mice [87] and that saponins from P. japonicus protect against alcohol-induced hepatic injury in mice by up-regulating the expression of glutathione peroxidase 3, SOD1 and SOD3 [88] . It has been demonstrated that Rb2 can significantly activate Cu, Zn-SOD gene 1 through the transcription factor activating protein 2-binding site in human HepG2 hepatoma cells (Table 3 ) [89] and that Rb1 protects endothelial cells from H 2 O 2 -induced cell senescence by modulating redox status [90] . However, the protective effect of P. ginseng and ginsenosides in ALS are still unclear.
Multiple sclerosis
Multiple sclerosis (MS) is a chronic immune-mediated infl ammatory demyelinating and neurodegenerative disorder of the CNS. It constitutes the most common nontraumatic cause of neurological disability among young adults and there is an increasing female predominance in North America and Western Europe. Partially known genetic and environmental factors constitute the etiology, which characterize complex genetic diseases [91] [92] [93] . Symptoms of MS commonly include physical (visions, balance problems and dizziness, fatigue, bladder problems, and stiffness and/or spasms), sensory, memory, cognitive, emotional, and sexual problems [91] [92] [93] . Numerous studies have directly led to the development of three medications approved for MS: IFN-β, glatiramer acetate, and the combination of mitoxantrone and natalizumab [94] . However, these drugs have limited therapeutic effect in stopping the onset and progression of MS and also have several other drawbacks that include cost, the need for intramuscular or subcutaneous injection, and occasionally infection/irritation after injection [95] . Developing an effective new drug would be of great clinical benefi t in the prevention and treatment of MS.
Ginsan extracts
An acidic polysaccharide of P. ginseng (APG), commonly called ginsan, is a purifi ed acidic polysaccharide extracted from the roots of P. ginseng (Table 3 ) [96] . Recently, Hwang et al. [97] demonstrated that APG signifi cantly ameliorated the severity of experimental autoimmune encephalomyelitis (EAE), the animal model for human MS, by inhibiting the proliferation of autoreactive T cells as well as the production of the infl ammatory cytokines, IFN-γ, IL-1β and IL-17. More importantly, the depletion of CD25 + cells abrogated the benefi cial effects of APG treatment in mice with EAE. The authors also investigated whether APG could promote the generation of immunosuppressive regulatory T cells (Tregs) through the activation of the transcription factor, Foxp3 [97] . Based on these results, we are studying whether P. ginseng extract has a neuroprotective effect in myelin oligodendrocyte glycoprotein-stimulated EAE model of mice. We confi rmed that pretreatment with P. ginseng extract can delay the onset of clinical behavior and improve the severity of EAE (unpublished). However, it also has been reported in a single-center, randomized, double-blind, and placebo-controlled crossover pilot study that American ginseng does not improve fatigue in MS [98] . The study examined the safety and effi cacy of an escalating dose (100, 200, and 400 mg/d) of American ginseng over 6 wk in 56 subjects with MS and fatigue. There were no serious adverse events but fatigue in American ginseng group, as assessed by the fatigue severity scale, was not signifi cantly different from fatigue in the placebo group.
CONCLUSION
P. ginseng has been used for thousands of years as a traditional medicine in Asian countries. P. ginseng has extensive pharmacological actions and specifi c mechanism in the CNS. The major active ingredients of P. ginseng, ginsenosides, exhibit anti-inflammatory, anti-oxidant, and anti-apoptotic mechanisms and exert various effects involving stress and the immune system in the nervous system. Rd, Re, and Rg1 are effective in treatment of PD and Rb1, Rg1-3, Re, and Rh2 are effective in the treatment of AD. Based on the increasing literature regarding neuroprotective effects, P. ginseng and ginsenosides may potentially be useful as dugs for the treatment of PD and AD. However, how these neuroprotective effects relate to the structures of the ginsenoside is still not yet fully understood. Further neurological studies should include the mechanisms of action in more detail with emphasis on specifi city and the relationship between structure and function. The prevalence of HD, ALS, and MS are also increasing. However, little is known of the physiological and pharmacological actions of P. ginseng and ginsenosides in these neurological disorders. Future neurological studies involving P. ginseng and ginsenosides should include the therapeutic studies in both animal and human models for these diseases.
